Member Info for RorkesDrift

daily lfd testing

https://www.huffingtonpost.co.uk/entry/dustbin-collectors-prison-staff-and-military-to-get-daily-covid-tests-to-avoid-staff-shortages_uk_60ff0962e4b0a807eeb4e4b3

Please don't sing "my lord". You never know who might turn up

https://youtu.be/oTEoUHqluws

Little known fact that the collective noun for sausages (be they the thwacking kind or not) is a string. Hence the phrase "to string someone along"

I'm not sure what the collective noun for a big ******s on donkeys is but the single is Lordship.

We want to hear the "Eh Up the Whalers" any day now

Ah the sweet dulset tones of sausage

id like to know more about leakage from cancer cells post clevage but i guess thats what phase I is about

£1200 and no top slicing on the way

Insert big yellow thumb

I know - my first purchase was around 23p and I was aware affimers could be used in DX. When I looked at company website the Therapeutics and their potential looked to have escaped attention - I think if on Nasdaq we would be double the SP we are now.

One issue is the number of irons in the fire and maybe they have done the necessary and prioritised AVA006. The number of secret squirrel partnerships that we know of but have no detail implies Avacta are content to let others do the heavy lifting - at least takes pressure of the balance sheet.

Would be good if shareholders had an update on the non Ava006 therapeutics - not after a running commentary but status has changed - dates being one if them.

Once we have proof of concept I cannot see Avacta remaining independent. I also cannot see us going for less than £2.4B and that would be cheap. The £300B quoted by others sitting slightly higher up than me (think small horse) is probably as likely as a very unlikely thing.

It was - I think early 2020. Prof Waffle not updated market but that doesn't negate its another potential opportunity. I'm guessing preclinical not up to scratch so have had to do some more - elimination Pk would be a guess. (Is that the sweet sound of donkey hooves I hear approaching).

Ava004 is one of about six programs so hopefully we will hear something about one of them.

My prediction is RNs this week with 20% rise cause of ava006 first patient. I've been wrong before. Then we get hit with ava004 submission one month later - fully funded by mad UK business dash for lfd to keep doors open

AVA004 | PD-L1 Checkpoint Inhibitor
The PD-L1/PD-1 axis is a negative regulator of immune activation – that is, it turns off the immune response in tumours – and this “checkpoint” pathway is considered a foundational target for drug development within the immuno-oncology field. AVA004 is a novel Affimer-based agent that selectively binds to and inhibits the interaction of PD-L1 on tumour cells with PD-1 on immune cells and so prevents this signalling pathway inactivating T-cells in the tumour microenvironment. Pre-clinical pharmacodynamics and toxicology studies of AVA004 demonstrated marked pharmacological activity and the agent is well tolerated at effective doses with a wide margin of safety. In animal models, the AVA-004 PD-L1 inhibitor displayed pharmacokinetics properties distinct from currently approved PD-L1 antibodies.

Putting to one side the timeline has been missed by a mile, things seem very quiet in relation to Ava004. This program formsba cornerstone of the therapeutic use of affirmers

From the website

nd these two main programmes, the company is exploring a number of I-O antagonists and agonists, and other pre|CISION™ pro-drugs, to support future programmes and partnering.

Click on the red bars in the pipeline infographic below for more information.

pre|CISION™ AVA6000 | FAP-Activated Doxorubicin Prodrug
Pre Clinical
AVA004 | PD-L1 Checkpoint Inhibitor
Pre Clinical
AVA021 | PD-L1 Affimer® / LAG-3 Affimer Bispecific Checkpoint Inhibitor
Pre Clinical
AVA027 | PD-L1 Affimer® / TGF? Trap Bispecific
Pre Clinical
TMAC® AVA04-VbP | PD-L1 Affimer® / I-DASH Inhibitor
Lead Optimisation
Oncology – Undisclosed Checkpoint Inhibitor
Lead Optimisation
Vascularization Disorders – Undisclosed Target
Lead Optimisation
Affimer-Drug Conjugate – Undisclosed Oncology Target
Lead Optimisation
Cell and Gene Therapies
Lead Optimisation
CLOSE
AVA004 | PD-L1 Checkpoint Inhibitor
The PD-L1/PD-1 axis is a negative regulator of immune activation – that is, it turns off the immune response in tumours – and this “checkpoint” pathway is considered a foundational target for drug development within the immuno-oncology field. AVA004 is a novel Affimer-based agent that selectively binds to and inhibits the interaction of PD-L1 on tumour cells with PD-1 on immune cells and so prevents this signalling pathway inactivating T-cells in the tumour microenvironment. Pre-clinical pharmacodynamics and toxicology studies of AVA004 demonstrated marked pharmacological activity and the agent is well tolerated at effective doses with a wide margin of safety. In animal models, the AVA-004 PD-L1 inhibitor displayed pharmacokinetics properties distinct from currently approved PD-L1 antibodies.

Issue is a narrow therapeutic window. Not enough and epilepsy not controlled. Too much and side effects kick in

There are other drugs that have similar issue. Tacrolimus for immunosuppression (transplants etc) is one.

There are plenty of approaches to biosensors. The issue isn't finding recognition molecules. The problem is getting a product that gives a consistent readout for a given concentration

I'm thinking calprotectin will be the one avacta is focused on. Then there is D dimer.

Given Covid it would be good to have an accurate readout on interferon etc but all inflammatory markers - multi array test.

Many groups are working on biosensors - they are all struggling time get them to market. If one getsba breakthrough.....

My bet is a company such as thermo fisher, Roche, Abbott. They have the money to throw at multiple shots at goal

Alternatively wait for self test approval.

Be interesting to see if Avacta launch a bulk individual pack. The sort of thing employees could take home on a Friday.

A little App to upload photo to a company server would be useful

Company with 10 employees would need 10 x 5 tests. That's per week.

For a month its close to the 25 pack they already do but premium tests need to oooze quality rather than stack em high

Hic

If a company wants to reduce the number of employees that get pinged one way would be to stop currently asymptomatic employees attending work by self testing.

If you told them to watch a video and complete the training register every employee could be classed as "professional" and thus be able to do their own test

If Avacta had a marketing dept this video complete witgbtraining oack would be freely available to download

https://twitter.com/DocMoschos/status/1418479467333304323?s=19

Avacta rafioligand partner is on same science park as novartis.....

https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_mergers_and_acquisitions

Standard dose of dox is calculated on the basis of body surface area. As a single agent, the recommended standard starting dose of doxorubicin per cycle in adults is 60-75mg/m2 of body surface area.

In the trial the first dose is 80mg/m2. I presume the slight difference is due to the larger molecular weight when the linker is bound.

So from there dose keeps escalating but I cannot tell by how much.

In mice it went to 12x - so 720mg/m2 and that might be below the maximum tolerated dose.

If so cancer cells are being hit by a massive hit of what kills them

This is a hypothesis not a fact (who knows how it performs in humans).